Market Overview

UPDATE: Morgan Stanley Cuts PT to $27 on Sagent Pharmaceuticals; Progress Amid Soft Q1

Related SGNT
Benzinga's M&A Chatter for Wednesday January 13, 2016
Top 4 NASDAQ Stocks In The Drugs-Generic Industry With The Lowest PEG Ratio

Morgan Stanley lowers its price from $28 to $27 on Overweight-rated Sagent Pharmaceuticals (NASDAQ: SGNT) following Q1 results coming in below expectations.

Morgan Stanley notes, "1Q12 revenue was below expectations, but positive pipeline and contracting updates support our long-term thesis of a broadening and profitable base driving revenue growth and margin leverage in an injectables market with attractive fundamentals."

SGNT closed at $16.88 on Friday.

Latest Ratings for SGNT

Jan 2016Deutsche BankMaintainsBuy
Jan 2016JP MorganInitiates Coverage onNeutral
Nov 2015Deutsche BankMaintainsBuy

View More Analyst Ratings for SGNT
View the Latest Analyst Ratings

Posted-In: Morgan StanleyAnalyst Color Price Target Reiteration Pre-Market Outlook Analyst Ratings


Related Articles (SGNT)

View Comments and Join the Discussion!

Get Benzinga's Newsletters